The Scottish Medicines Consortium (SMC) has approved Fycompa to be used as a treatment for epilepsy. The drug is approved for use in Scotland’s hospitals and clinics. Fycompa (perampanel) won its approval as a second-line adjunctive treatment for patients with refractory partial-onset epilepsy.

Epilepsy is on the rise in Scotland, with 54,000 people currently diagnosed with the condition. That number is steadily rising. This fact has made it very important for doctors to find a good prescription medication to combat the symptoms.

“This approval from the SMC is a positive step in the management of people with epilepsy in Scotland,” says professor Martin Brodie, professor of medicine and clinical pharmacology at the University of Glasgow and director of the Epilepsy Unit at Western Infirmary in the city. “Uncontrolled seizures have a severe impact on everyday function and quality of life and so we look forward to the possibility of being able to offer our epilepsy patients a new treatment option.”

Epilepsy is a serious neurological disorder that causes patients to suffer from seizures. The condition affects millions of people worldwide, and is often treated with dangerous anti-seizure drugs like Topamax, which is linked to babies being born with birth defects, including PPHN, oral clefts, spina bifida and neural tube defects when the mothers take the pills while pregnant. Topamax use is often dangerous because doctors have to guess which dosage to use on patients in order to find the right one. This makes Topamax even more dangerous because the side effects are often experienced in dramatic ways before the right dosage is found.

If your baby has suffered from birth defects after being exposed to Topamax in-utero, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Topamax lawsuits and may be able to help you recover money for your child’s injury.